129 related articles for article (PubMed ID: 16187287)
1. Antitumor efficacy of a novel polymer-peptide-drug conjugate in human tumor xenograft models.
Chau Y; Padera RF; Dang NM; Langer R
Int J Cancer; 2006 Mar; 118(6):1519-26. PubMed ID: 16187287
[TBL] [Abstract][Full Text] [Related]
2. Investigation of targeting mechanism of new dextran-peptide-methotrexate conjugates using biodistribution study in matrix-metalloproteinase-overexpressing tumor xenograft model.
Chau Y; Dang NM; Tan FE; Langer R
J Pharm Sci; 2006 Mar; 95(3):542-51. PubMed ID: 16419048
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and characterization of dextran-peptide-methotrexate conjugates for tumor targeting via mediation by matrix metalloproteinase II and matrix metalloproteinase IX.
Chau Y; Tan FE; Langer R
Bioconjug Chem; 2004; 15(4):931-41. PubMed ID: 15264885
[TBL] [Abstract][Full Text] [Related]
4. Antitumor properties and toxicity of dextran-methotrexate conjugates are dependent on the molecular weight of the carrier.
Nevozhay D; Budzynska R; Kanska U; Jagiello M; Omar MS; Boratynski J; Opolski A
Anticancer Res; 2006; 26(2A):1135-43. PubMed ID: 16619515
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of anti-tumor activity of hybrid peptide in conjugation with carboxymethyl dextran via disulfide linkers.
Gaowa A; Horibe T; Kohno M; Tabata Y; Harada H; Hiraoka M; Kawakami K
Eur J Pharm Biopharm; 2015 May; 92():228-36. PubMed ID: 25801495
[TBL] [Abstract][Full Text] [Related]
6. Novel insulin-like growth factor-methotrexate covalent conjugate inhibits tumor growth in vivo at lower dosage than methotrexate alone.
McTavish H; Griffin RJ; Terai K; Dudek AZ
Transl Res; 2009 Jun; 153(6):275-82. PubMed ID: 19446281
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and therapeutic evaluation of an aptide-docetaxel conjugate targeting tumor-associated fibronectin.
Kim H; Lee Y; Lee IH; Kim S; Kim D; Saw PE; Lee J; Choi M; Kim YC; Jon S
J Control Release; 2014 Mar; 178():118-24. PubMed ID: 24462899
[TBL] [Abstract][Full Text] [Related]
8. Activity of dendrimer-methotrexate conjugates on methotrexate-sensitive and -resistant cell lines.
Gurdag S; Khandare J; Stapels S; Matherly LH; Kannan RM
Bioconjug Chem; 2006; 17(2):275-83. PubMed ID: 16536456
[TBL] [Abstract][Full Text] [Related]
9. A novel matrix metalloproteinase inhibitor, FYK-1388 suppresses tumor growth, metastasis and angiogenesis by human fibrosarcoma cell line.
Shinoda K; Shibuya M; Hibino S; Ono Y; Matsuda K; Takemura A; Zou D; Kokubo Y; Takechi A; Kudoh S
Int J Oncol; 2003 Feb; 22(2):281-8. PubMed ID: 12527923
[TBL] [Abstract][Full Text] [Related]
10. Self-sensibilized polymeric prodrug co-delivering MMP-9 shRNA plasmid for combined treatment of tumors.
Tang Q; Ma X; Zhang Y; Cai X; Xue W; Ma D
Acta Biomater; 2018 Mar; 69():277-289. PubMed ID: 29369806
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo antitumor activity of methotrexate conjugated to human serum albumin in human cancer cells.
Wosikowski K; Biedermann E; Rattel B; Breiter N; Jank P; Löser R; Jansen G; Peters GJ
Clin Cancer Res; 2003 May; 9(5):1917-26. PubMed ID: 12738750
[TBL] [Abstract][Full Text] [Related]
12. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
[TBL] [Abstract][Full Text] [Related]
13. The in vivo antitumor activity of LHRH targeted methotrexate-human serum albumin nanoparticles in 4T1 tumor-bearing Balb/c mice.
Taheri A; Dinarvand R; Ahadi F; Khorramizadeh MR; Atyabi F
Int J Pharm; 2012 Jul; 431(1-2):183-9. PubMed ID: 22531853
[TBL] [Abstract][Full Text] [Related]
14. The effect of the substitution level of some dextran-methotrexate conjugates on their antitumor activity in experimental cancer models.
Nevozhay D; Budzynska R; Jagiello M; Kanska U; Omar MS; Opolski A; Wietrzyk J; Boratynski J
Anticancer Res; 2006; 26(3A):2179-86. PubMed ID: 16827162
[TBL] [Abstract][Full Text] [Related]
15. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
16. Preparation and antitumor activity of a polymeric derivative of methotrexate.
Zhou G; Cheng X; Wu S; Jiang X; Shi X; Chen J; Zhang J; Zhao J
Am J Med Sci; 2012 Oct; 344(4):294-9. PubMed ID: 22885620
[TBL] [Abstract][Full Text] [Related]
17. MMPs-specific PEGylated peptide-DOX conjugate micelles that can contain free doxorubicin.
Lee GY; Park K; Kim SY; Byun Y
Eur J Pharm Biopharm; 2007 Nov; 67(3):646-54. PubMed ID: 17499491
[TBL] [Abstract][Full Text] [Related]
18. Pre-clinical evaluation of a methotrexate-albumin conjugate (MTX-HSA) in human tumor xenografts in vivo.
Burger AM; Hartung G; Stehle G; Sinn H; Fiebig HH
Int J Cancer; 2001 Jun; 92(5):718-24. PubMed ID: 11340578
[TBL] [Abstract][Full Text] [Related]
19. Biological evaluation of a novel doxorubicin-peptide conjugate for targeted delivery to EGF receptor-overexpressing tumor cells.
Ai S; Duan J; Liu X; Bock S; Tian Y; Huang Z
Mol Pharm; 2011 Apr; 8(2):375-86. PubMed ID: 21241067
[TBL] [Abstract][Full Text] [Related]
20. A conjugate of camptothecin and a somatostatin analog against prostate cancer cell invasion via a possible signaling pathway involving PI3K/Akt, alphaVbeta3/alphaVbeta5 and MMP-2/-9.
Sun LC; Luo J; Mackey LV; Fuselier JA; Coy DH
Cancer Lett; 2007 Feb; 246(1-2):157-66. PubMed ID: 16644105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
